LC-MS/MS-based investigation of pharmacokinetic interactions between CYP3A4 substrates enzalutamide and repaglinide in rats.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: comorbidities
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Co-administration of these drugs in rats allowed assessment of the potential DDI. We report that ENZ, as a CYP3A4 inducer, alters the REP pharmacokinetic parameters, and clinicians must consider this before prescribing them.
Polypharmacy is a common phenomenon in older patients with comorbidities.
APA
Navitha Reddy G, Kumar Palepu MS, Sonti R (2025). LC-MS/MS-based investigation of pharmacokinetic interactions between CYP3A4 substrates enzalutamide and repaglinide in rats.. Analytical methods : advancing methods and applications, 17(47), 9565-9574. https://doi.org/10.1039/d5ay01451d
MLA
Navitha Reddy G, et al.. "LC-MS/MS-based investigation of pharmacokinetic interactions between CYP3A4 substrates enzalutamide and repaglinide in rats.." Analytical methods : advancing methods and applications, vol. 17, no. 47, 2025, pp. 9565-9574.
PMID
41170666 ↗
Abstract 한글 요약
Polypharmacy is a common phenomenon in older patients with comorbidities. Prostate cancer patients often have diabetes complications, making them prone to administering multiple medications. Here, we explored the pharmacokinetic interactions between Enzalutamide (ENZ), prescribed for treating metastatic castration-resistant prostate cancer, and repaglinide (REP), used for type-2 diabetes. A novel, simple, and sensitive LC-MS/MS bioanalytical method was developed to simultaneously estimate ENZ and REP in rat plasma, aiding pharmacokinetic drug-drug interaction evaluation. Co-administration of these drugs in rats allowed assessment of the potential DDI. We report that ENZ, as a CYP3A4 inducer, alters the REP pharmacokinetic parameters, and clinicians must consider this before prescribing them.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- SpNeigh: spatial neighborhood and differential expression analysis for high-resolution spatial transcriptomics.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- The tumor microenvironment as a key regulator of radiotherapy response.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
- Advances in green-synthesized magnetic nanoparticles for targeted cancer therapy: mechanisms, applications, and future perspectives.
- SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.